PTI-2

PTI-2
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name N-(2-methoxyethyl)-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)propan-2-amine;
JSmol)	Interactive image;
	SMILES CCCCCN1C=C(C2=CC=CC=C21)C3=NC(CN(C(C)C)CCOC)=CS3;
	InChI InChI=1S/C23H33N3OS/c1-5-6-9-12-26-16-21(20-10-7-8-11-22(20)26)23-24-19(17-28-23)15-25(18(2)3)13-14-27-4/h7-8,10-11,16-18H,5-6,9,12-15H2,1-4H3; Key:PSAKYYVEVVAWJL-UHFFFAOYSA-N;

PTI-2 (SGT-49) is an

Organon and subsequently further researched by Merck.^[2]^[3]^[4]

References

^ "PTI-2". Cayman Chemical. Retrieved 8 July 2015.
^ US 7700634, Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR, "(Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor.", issued 20 April 2010, assigned to Organon NV
^ US 7763732, Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T, "Indole Derivatives", issued 27 July 2010, assigned to Organon NV
PMID 21316962
.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=PTI-2&oldid=1142746192"